IP Library Granted Patent US 8,034,368
Granted Patent B2
US 8,034,368 · App. 12/058,298 · Granted Oct 11, 2011

Drug delivery device for providing local analgesia, local anesthesia or nerve blockage

Assignee: Innocoll Technologies Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,034,368
App. No.
12/058,298
Granted
Oct 11, 2011
Kind
B2
Abstract

The invention relates to a drug delivery device for providing local analgesia, local anesthesia or nerve blockade at a site in a human or animal in need thereof, the device comprising a fibrillar collagen matrix; and at least one drug substance selected from the group consisting of amino amide anesthetics, amino ester anesthetics and mixtures thereof, the at least one drug substance being substantially homogeneously dispersed in the collagen matrix, and the at least one drug substance being present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about one day after administration.

Claims (23)

1. A drug delivery device for providing local analgesia, local anesthesia or nerve blockade at a site in a human or animal in need thereof, the device comprising a fibrillar collagen matrix; and at least one drug substance selected from the group consisting of amino amide anesthetics, amino ester anesthetics and mixtures thereof, the at least one drug substance being substantially homogeneously dispersed in the collagen matrix, and the at least one drug substance being present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about one day after administration.

2. The drug delivery device of claim 1 , wherein the at least one drug substance is present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about two days after administration.

3. The drug delivery device of claim 1 , wherein the at least one drug substance is present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about three days after administration.

4. The drug delivery device of claim 1 , wherein the at least one drug substance is an amino amide anesthetic selected from the group comprising Bupivacaine, Levobupivacaine, Lidocaine, Mepivacaine, Prilocaine, Ropivacaine, Articaine, Trimecaine and their salts and prodrugs.

5. The drug delivery device of claim 1 , wherein the at least one drug substance is an amino amide anesthetic selected from bupivacaine and salts and pro drugs thereof.

6. The drug delivery device of claim 1 , wherein the fibrillar collagen matrix is a Type I collagen matrix.

7. The drug delivery device of claim 1 , wherein the fibrillar collagen matrix is a Type I collagen matrix and the at least one drug substance is an amino amide anesthetic selected from bupivacaine and salts and prodrugs thereof.

8. The drug delivery device of claim 7 , wherein the drug delivery device comprises a plurality of collagen sponges, each collagen sponge containing about 3.6 to about 8.0 mg/cm 3 type I collagen and about 2.0 to about 6.0 mg/cm 3 bupivacaine hydrochloride.

9. The drug delivery device of claim 7 , wherein the drug delivery device comprises a plurality of collagen sponges, each collagen sponge containing about 5.6 mg/cm 3 type I collagen and about 4.0 mg/cm 3 bupivacaine hydrochloride.

10. A method for providing local analgesia, local anesthesia or nerve blockade in a human or animal in need thereof, the method comprising administering at a site in a human or animal in need thereof a drug delivery device comprising a fibrillar collagen matrix; and at least one drug substance selected from the group consisting of amino amide anesthetics, amino ester anesthetics and mixtures thereof, the at least one drug substance being substantially homogeneously dispersed in the collagen matrix, and the at least one drug substance being present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about one day after administration.

11. The method of claim 10 , wherein the at least one drug substance is present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about two days after administration.

12. The method of claim 10 , wherein the at least one drug substance is present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about three days after administration.

13. The method of claim 10 , wherein the at least one drug substance is an amino amide anesthetic selected from the group comprising Bupivacaine, Levobupivacaine, Lidocaine, Mepivacaine, Prilocaine, Ropivacaine, Articaine, Trimecaine and their salts and prodrugs.

14. The method of claim 10 , wherein the at least one drug substance is an amino amide anesthetic selected from bupivacaine and salts and prodrugs thereof.

15. The method of claim 10 , wherein the fibrillar collagen matrix is a Type I collagen matrix.

16. The method of claim 10 , wherein the fibrillar collagen matrix is a Type I collagen matrix and the at least one drug substance is an amino amide anesthetic selected from bupivacaine and salts and prodrugs thereof.

17. The method of claim 16 , wherein the drug delivery device comprises a plurality of collagen sponges, each collagen sponge containing about 3.6 to about 8.0 mg/cm 3 type I collagen and about 2.0 to about 6.0 mg/cm 3 bupivacaine hydrochloride.

18. The method of claim 16 , wherein the drug delivery device comprises a plurality of collagen sponges, each collagen sponge containing about 5.6 mg/cm 3 type I collagen and about 4.0 mg/cm 3 bupivacaine hydrochloride.

19. The method of claim 10 , wherein the method is for providing local analgesia, local anesthesia or nerve blockade in a human following laparotomy.

20. The method of claim 10 , wherein the method is for providing local analgesia, local anesthesia or nerve blockade in a human following orthopedic, abdominal, gynecological or thoracic surgical procedures.

21. The method of claim 17 , wherein the method is for providing local analgesia, local anesthesia or nerve blockade in a human following orthopedic, abdominal, gynecological or thoracic surgical procedures.

22. The method of claim 18 , wherein the method is for providing local analgesia, local anesthesia or nerve blockade in a human following orthopedic, abdominal, gynecological or thoracic surgical procedures.

23. The method of claim 10 , wherein the drug delivery device comprises a plurality of collagen sponges and wherein at least one sponge is placed adjacent the surgical site, at least one sponge is placed across the incision in the wall of the body cavity and at least one sponge is placed between the sheath and skin around the incision.

Assignments (6)
SECURITY INTEREST Recorded Nov 7, 2023
From: OAKTREE FUND ADMINISTRATION, LLC
To: GURNET FINANCE SA
Reel/Frame 065484/0092 →
SECURITY INTEREST Recorded Feb 24, 2022
From: INNOCOLL PHARMACEUTICALS LIMITED
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 059096/0842 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ADDRESS INSIDE THE ASSIGNMENT DOCUMENT PREVIOUSLY RECORDED AT REEL: 036806 FRAME: 0528. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Feb 8, 2016
From: INNOCOLL TECHNOLOGIES LIMITED
To: INNOCOLL PHARMACEUTICALS LIMITED
Reel/Frame 037739/0093 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS. PREVIOUSLY RECORDED ON REEL 036593 FRAME 0472. ASSIGNOR(S) HEREBY CONFIRMS ASSIGNMENT. Recorded Sep 24, 2015
From: INNOCOLL TECHNOLOGIES LIMITED
To: INNOCOLL PHARMACEUTICALS LIMITED
Reel/Frame 036806/0528 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 17, 2015
From: INNOCOLL TECHNOLOGIES LIMITED
To: INNOCOLL PHARMACEUTICALS LIMITED
Reel/Frame 036593/0472 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2008
From: MYERS, MICHAEL; REGINALD, PHILIP WALLACE
To: INNOCOLL TECHNOLOGIES LIMITED
Reel/Frame 021091/0599 →
Continuity (2)
Continuation In Part 11692337 · Mar 28, 2007
Related Publication 20080241245A1 · Oct 2, 2008